AI tool to predict outcomes in metastatic lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing whether artificial intelligence can help predict how well people with advanced non-small cell lung cancer (NSCLC) respond to immunotherapy or chemo-immunotherapy. If you have stage IV NSCLC and have started this treatment, your data may help build a better prediction tool.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung cancer called non-small cell lung cancer (NSCLC).
- Your cancer must be stage IV (advanced, not able to be cured with local treatments like surgery or radiation).
- You need to have received at least one cycle of immunotherapy alone or in combination with chemotherapy.
- You must be available for follow-up visits as part of standard care.
- You cannot have other types of lung cancer (like small cell lung cancer).
- You should not be enrolled in other clinical trials with different drug combinations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
This trial tests whether artificial intelligence can help doctors plan better treatment for non-small cell lung cancer (NSCLC). A team of specialists will use AI tools alongside their usual approach to see if it improves care and safety.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
This trial uses special tests (like looking at genes and proteins) to better understand which patients with non-small cell lung cancer (NSCLC) will benefit most from immunotherapy given before surgery. It aims to create a tool to predict treatment success.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.